Lifespan has reached an impressive peak in America. A person born in 2024 can expect to live an average of 79 years,¹ with U.S. Census Bureau projections pushing that number to 85.6 by 2060. But as longevity rises across the board, are Americans actually cheering the prospect of living longer?

It’s complicated.

Today, longevity for longevity’s sake has lost its luster. Instead, healthspan – a life measured by how long we live without significant health issues – is the new prevailing consumer mindset. While the term was coined in the late 1980s, it’s finally emerging from obscure academic jargon as a potent consumer driver, reshaping how people think about aging and redefining pharma’s role in that process.

For pharmaceutical marketers and communicators, navigating this evolution means leaving passive disease management behind and adopting proactive healthspan-optimizing strategies. Here, we’ll discuss how and why companies can adapt to drive growth in the burgeoning healthy aging market.

Decoding the Healthspan Shift: Wellness Over Appearance

To quantify this profound cultural shift, GCI Health undertook a comprehensive study of 3,000 U.S. adults between the ages of 25 and 54. The report, “From Live Long to Live Well: The New Healthy Aging Paradigm,”² offers insights for pharmaceutical companies – long considered the vanguards of the life-extending movement.

While it’s not surprising that most people would choose to live in good health, the data reveals the surprising fact that most people would be willing to sacrifice years of life to avoid poor health. An overwhelming majority (86%) of adults would rather live to age 80 remaining healthy, active and independent until the end than live to 90 in poor health. While the terms “lifespan” and “longevity” might be more familiar, “healthy aging” is where emotional equity lies. So, while lifespan is what people know, healthy aging is what they feel.

The focus on healthspan has created a clear preference of mind over body. Two-thirds of adults would choose to age with a sharp, clear mind in a body with significant physical decline over a strong, mobile body but with significant cognitive decline. This desire is particularly pronounced for women. And, even in our more appearance-focused culture, long-term cognitive health consistently outranks vanity. When presented with a hypothetical offer of $500 and five free hours a month for “anti-aging,” 80% would spend it on activities to improve their long-term health versus spending it on cosmetic treatments or products to improve their appearance.

The Healthy Aging Uber Consumers

To heed today’s healthy aging call, pharma must abandon outdated thinking that the prime consumer target is a baby boomer monolith. The youngest adult generation, Gen Z, is actually driving the healthspan mindset, a finding reaffirmed by a Precedence Research study,³ noting that “Among Gen Z and millennials, wellness is an everyday ritual, not just an occasional activity.” The study found that in the U.S., Gen Z and millennials spend 41% of their annual budget on wellness annually, versus 28% for those aged 58+. This upends the traditional “urgency spectrum,” which assumes that only older adults focus on aging.

The GCI Health research also reveals the rise of the most highly engaged consumer segment: The “Healthspan Hacker.” While Healthspan Hackers span generations, they’re defined by their approach, actively “hacking” their biology and optimizing their healthspan through a combination of healthy behaviors and medical interventions. Contrary to popular opinion, interventions like GLP-1s or cosmetic procedures are not a shortcut for these consumers; they’re an integral part of their approach to holistic health.

Interestingly, while GLP-1s are still primarily prescribed for obesity, among respondents taking GLP-1s, one-quarter note their primary reason for doing so is to improve their long-term metabolic health. This illuminates new opportunities for preventative health and “bio-hacking” pharmaceutical solutions.

The Trust Deficit and the HCP Anchor

With Open AI reporting⁴ that 40 million people globally submit health queries to ChatGPT daily, AI is rapidly emerging as a trusted source for health and wellness information. The trust placed in healthcare professionals (HCPs), however, is unwavering. The healthspan research⁵ reveals that nine in 10 adults trust the information they receive from HCPs – outpacing medical websites, AI, influencers and social channels. HCP trust is even more pronounced among caregivers. Caregivers consult HCPs and medical websites significantly more than non-caregivers, representing a highly receptive audience for healthy aging communications.

The Healthy Aging Rx for Pharma

The data spotlights a stark reality in consumer perceptions about pharma’s effectiveness in helping people achieve their healthy aging goals. A strong majority of adults (72%) show skepticism of modern medicine’s support of proactive, healthy aging, agreeing that modern medicine is better at extending lifespan than it is at extending healthspan.

This shift in consumer expectation coincides with a shift in modern medicine. Breakthrough innovations have successfully transformed once-fatal diseases – cancer, cardiovascular disease, HIV and cystic fibrosis, for example – into manageable chronic conditions. Historically, the industry’s ultimate victory was helping people live longer. Today, the mandate has evolved: Pharma must not only develop therapies that add years to life but also add life to years.

To close the gap and capture the value of the healthspan market, pharma companies should focus on these actionable strategies:

• Reframe communications from “management” to “optimization”: Messaging should emphasize how treatments or therapies help patients maintain their active lifestyles, cognitive abilities and independence. This means highlighting quality-of-life benefits – such as ease of at-home administration over hospital visits. Additionally, in clinical trials, quality-of-life endpoints often take a backseat to efficacy endpoints in communications. Highlighting a therapy’s impact on physical, psychological and social functioning must also be prioritized to convey its full value to patients.
• Consider new consumer audiences: It’s critical for pharma to recognize that interest in healthy aging starts early. Younger consumers (Gen Z) and Healthspan Hackers are eager to adopt long-term preventative care. By showcasing treatments that target multiple morbidities before they manifest and targeting unbranded educational campaigns to younger audiences, pharma can help this generation be more proactive about their health.
• Empower HCPs as healthspan educators: HCPs remain the most trusted voices in healthcare, and pharma must equip providers with tools that support proactive aging conversations. Developing programs that, where possible, transition from a “diagnose-and-treat" model to a “prevent-and-optimize" model will be critical. Giving HCPs the resources to discuss cognitive preservation and metabolic health early will help pharma build trust among HCPs and their patients.

For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial opportunity. By aligning R&D, marketing and communications with this new healthy aging paradigm, pharma can shift consumer sentiment from skeptical to trusted and redefine its role from a life extender to a lifestyle partner.

Sources

1. https://www.cdc.gov/nchs/products/databriefs/db548.html
2. https://gcihealth.com/reports/healthspan/
3. The Wellness Transformation: Gen Z and Millennials Redefining Wellness Culture
4. OpenAI: AI as a Healthcare Ally [Jan 2026]
5. https://gcihealth.com/reports/healthspan/